The yeast Saccharomyces cerevisiae is the paradigm of a eukaryotic model organism. In virtue of a substantial degree of functional conservation, it has been extensively exploited to understand multiple aspects of the genetic, molecular, and cellular biology of human disease. Many aspects of cell signaling in cancer, aging, or metabolic diseases have been tackled in yeast. Here, we review the strategies undertaken throughout the years for the development of humanized yeast models to study regulated cell death (RCD) pathways in general, and specifically, those related to innate immunity and inflammation, with an emphasis on pyroptosis and necroptosis. Such pathways involve the assembly of distinct modular signaling complexes such as the inflammasome and the necrosome. Like other supramolecular organizing centers (SMOCs), such intricate molecular arrangements trigger the activity of enzymes, like caspases or protein kinases, culminating in the activation of lytic pore-forming final effectors, respectively, Gasdermin D (GSDMD) in pyroptosis and MLKL in necroptosis. Even though pathways related to those governing innate immunity and inflammation in mammals are missing in fungi, the heterologous expression of their components in the S. cerevisiae model provides a “cellular test tube” to readily study their properties and interactions, thus constituting a valuable tool for finding novel therapies.
FENIB (familial encephalopathy with neuroserpin inclusion bodies) is a human monogenic disease caused by point mutations in the SERPINI1 gene, characterized by the intracellular deposition of polymers of neuroserpin (NS), which leads to proteotoxicity and cell death. Despite the different cell and animal models developed thus far, the exact mechanism of cell toxicity elicited by NS polymers remains unclear. Here, we report that human wild-type NS and the polymerogenic variant G392E NS form protein aggregates mainly localized within the endoplasmic reticulum (ER) when expressed in the yeast S. cerevisiae. The expression of NS in yeast delayed the exit from the lag phase, suggesting that NS inclusions cause cellular stress. The cells also showed a higher resistance following mild oxidative stress treatments when compared to control cells. Furthermore, the expression of NS in a pro-apoptotic mutant strain-induced cell death during aging. Overall, these data recapitulate phenotypes observed in mammalian cells, thereby validating S. cerevisiae as a model for FENIB.
Caspases are a family of cysteine proteases that play an essential role in inflammation, apoptosis, cell death, and development. Here we delve into the effects caused by heterologous expression of human Caspase-1 in the yeast Saccharomyces cerevisiae and compare them to those of Caspase-8. Overexpression of both caspases in the heterologous model led to their activation, and caused mitochondrial depolarization, ROS production, damage to different organelles, and cell death. All these effects were dependent on their protease activity, and Caspase-8 was more aggressive than Caspase-1. Growth arrest could be at least partially explained by dysfunction of the actin cytoskeleton as a consequence of the processing of the yeast Bni1 formin, which we identify here as a likely direct substrate of both caspases. Through the modulation of the GAL1 promoter by using different galactose:glucose ratios in the culture medium, we have established a scenario in which Caspase-1 is sufficiently expressed to become activated while yeast growth is not impaired. Finally, we used the yeast model to explore the role of death-fold domains (DD) of both caspases in their activity. Peculiarly, the DDs of either caspase showed an opposite involvement in its intrinsic activity, as the deletion of the caspase activation and recruitment domain (CARD) of Caspase-1 enhanced its activity, while the deletion of the death effector domain (DED) of Caspase-8 diminished it. We propose the yeast model as a useful and manageable tool to explore Caspase-1 structure-function relationships, the impact of mutations or the activity of putative inhibitors or regulators.
The yeast Saccharomyces cerevisiae is the paradigm of a eukaryotic model organism. In virtue of a substantial degree of functional conservation, it has been extensively exploited to understand multiple aspects of the genetics, molecular and cellular biology of human disease. Many aspects of cell signaling in cancer, aging or metabolic diseases, have been tackled in yeast. Here, we review the strategies undertaken through the years for the development of humanized yeast models to study regulated cell death (RCD) pathways in general, and specifically those related to innate immunity and inflammation, with emphasis in pyroptosis and necroptosis. Such pathways involve the assembly of distinct modular signaling complexes such as the inflammasome and the necrosome. Like other supramolecular organizing centers (SMOCs), such intricate molecular arrangements trigger the activity of enzymes, like caspases or protein kinases, culminating in the activation of lytic pore-forming final effectors, respectively gasdermin D (GSDMD) in pyroptosis and MLKL in necroptosis. Even though pathways related to those governing innate immunity and inflammation in mammals are missing in fungi, heterologous expression of their components in the S. cerevisiae model provides a “cellular test tube” to readily study their properties and interactions, thus constituting a valuable tool for finding novel therapies.
Disconnects between in vitro and in vivo results in experimental biology have long been recognized as potential hurdles to understanding health and disease. A prototypical example of such a disconnect is the NLRP3 inflammasome, which mediates inflammation in diverse settings of disease and protective immunity1,2. Activation of the NLRP3 inflammasome in vitro requires two signals: (1) priming by pathogen-associated molecular patterns such as bacterial lipopolysaccharides and (2) activation by molecules that disrupt cellular homeostasis1,3. By contrast, the NLRP3 inflammasome in vivo is activated by lipopolysaccharide alone. The mechanisms that underlie the difference between in vitro and in vivo activation of the NLRP3 inflammasome are undefined. Here we report that extracellular matrix (ECM) stiffness is a determinant of NLRP3 activities and that in vitro systems using physiological ECM stiffness enable one-signal in vivo-like NLRP3 activities to occur in human and mouse phagocytes. Physiological ECM stiffness induced expression of the transcription factor NRF2, which was found to be necessary for one-signal NLRP3 activation. Mechanistically, we identify Panx1 as an NRF2-regulated gene that promotes NLRP3 activity. Macrophages derived from the stiff matrix of the bone-osteoclasts-had reduced NRF2 levels and impaired NLRP3 activity. Moreover, alveolar macrophages from patients with pulmonary fibrosis displayed reduced NRF2 activity. Finally, NRF2 was required for antitumour immunity induced by cancer vaccines consisting of NLRP3 agonistic adjuvants. These findings indicate that NRF2 may be a transcriptional checkpoint that controls NLRP3 inflammasome activity.